Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Locus Biosciences

Main focus: New treatments against bacterial infections

Company stage: Clinical

Diseases: Urinary tract infection, other infections

Genome editing tool: CRISPR-Cas3

Funding stage: Private

Location: North Carolina, USA

Website: https://www.locus-bio.com/

Partners: Janssen Pharma

Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus uses CRISPR-Cas3 crPhages as the base of their therapies. The phages are designed using machine learning in order to optimise effectiveness against new bacterial targets.

Tags

HashtagLOCUS Biosciences, Inc.

close
Search CRISPR Medicine